(Q37502929)

20 August 2017

1 reference

title

Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects (English)

1 reference

20 August 2017

0 references

3

1 reference

20 August 2017

2

Klaus Pfizenmaier

1 reference

20 August 2017

Jeannette Gerspach

1

1 reference

20 August 2017

1 July 2009

1 reference

20 August 2017

1 reference

20 August 2017

35

1 reference

20 August 2017

4

1 reference

20 August 2017

364-372

1 reference

Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature

20 August 2017

1 reference

Critical role of TNF receptor type-2 (p75) as a costimulator for IL-2 induction and T cell survival: a functional link to CD28.

21 January 2018

1 reference

TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo.

21 January 2018

1 reference

Targeted bioactivity of membrane-anchored TNF by an antibody-derived TNF fusion protein

21 January 2018

1 reference

Structure-activity profiles of Ab-derived TNF fusion proteins.

21 January 2018

1 reference

Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration

21 January 2018

1 reference

Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors

21 January 2018

1 reference

Cutting Edge: TNFR-Shedding by CD4+CD25+ Regulatory T Cells Inhibits the Induction of Inflammatory Mediators

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/BIOF.50

1 reference

20 August 2017

1 reference

PubMed ID

19484741